In investigating this, Bertolaccini et al. demonstrated that it prevented complement activation in vivo and in vitro, with lower C5a levels and reduced placental insufficiency with HCQ‐treatment in a mouse model of APS.165. This evidence concerns the gene C5AR1 and autoimmune polyendocrinopathy.